Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

BACKGROUND: Eribulin mesylate (ERI; Halaven®) is a microtubule inhibitor approved in the United States for metastatic breast cancer patients with at least two prior chemotherapy regimens for metastatic breast cancer, and in the European Union in locally advanced breast cancer or metastatic breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Qi, Hughes, Rachel, Neupane, Binod, Mickle, Kristin, Su, Yun, Chabot, Isabelle, Betts, Marissa, Kadambi, Ananth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244131/
https://www.ncbi.nlm.nih.gov/pubmed/34193107
http://dx.doi.org/10.1186/s12885-021-08446-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244131/
https://www.ncbi.nlm.nih.gov/pubmed/34193107
http://dx.doi.org/10.1186/s12885-021-08446-8

Ejemplares similares